18β-Glycyrrhetinic Acid Inhibits Osteoclastogenesis In Vivo and In Vitro by Blocking RANKL-Mediated RANK–TRAF6 Interactions and NF-κB and MAPK Signaling Pathways
Authors:
Open Access
- 20 June 2018
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 9, 647
Abstract
Bone metabolism is determined by a delicate balance between bone resorption by osteoclasts and bone formation by osteoblasts. The imbalance due to over-activated osteoclasts plays an important role in various diseases. Activation of NF-κB and MAPK signaling pathways by receptor activator of nuclear factor -κB ligand (RANKL) is vital for osteoclastogenesis. Here, we for the first time explored the effects of 18β-glycyrrhetinic acid (18β-GA), a pentacyclic triterpenoid found in the Glycyrrhiza glabra L roots, on RANKL-induced osteoclastogenesis, osteoclast functions and signaling pathways in vitro and in vivo. In bone marrow monocytes (BMMs) and RAW264.7 cells, 18β-GA inhibited osteoclastogenesis, decreased expression of TRAP, cathepsin K, CTR and MMP-9, blocked actin ring formation and compromised osteoclasts functions in a dose-dependent manner at an early stage with minimal effects on osteogenic and adipogenic differentiation of bone marrow mesenchymal stem cells (BMSCs). For underlying molecular mechanisms, 18β-GA inhibited RANKL-induced phosphorylation of p65, p50, and IκB, blocked p65 nuclear translocation and decreased the DNA-binding activity of NF-κB. Besides, 18β-GA inhibited the activation of the MAPK pathways. Co-immunoprecipitation showed that 18β-GA treatment blocked RANK–TRAF6 association at an upstream site. In vivo, 18β-GA treatment inhibited ovariectomy-induced osteoclastogenesis and reduced bone loss in mice. Overall, our results demonstrated that 18β-GA inhibited RANKL-induced osteoclastogenesis by inhibiting RANK expression in preosteoclasts and blocking the binding of RANK and TRAF6 which lead to the inhibition of NF-κB and MAPK signaling pathways. 18β-GA is a promising novel candidate in the treatment of osteoclast-related diseases such as postmenopausal osteoporosis.Keywords
Funding Information
- National Natural Science Foundation of China (91749204, 81771491, 31370958)
This publication has 42 references indexed in Scilit:
- Redundant miR-3077-5p and miR-705 mediate the shift of mesenchymal stem cell lineage commitment to adipocyte in osteoporosis bone marrowCell Death & Disease, 2013
- Cysteine proteinase inhibitors regulate human and mouse osteoclastogenesis by interfering with RANK signalingThe FASEB Journal, 2013
- Orai1‐mediated calcium entry plays a critical role in osteoclast differentiation and function by regulating activation of the transcription factor NFATc1The FASEB Journal, 2011
- Adverse Reactions and Drug–Drug Interactions in the Management of Women with Postmenopausal OsteoporosisCalcified Tissue International, 2011
- Differential effects between the loss of MMP-2 and MMP-9 on structural and tissue-level properties of boneJournal of Bone and Mineral Research, 2010
- Diphenylhydantoin Inhibits Osteoclast Differentiation and Function Through Suppression of NFATc1 SignalingJournal of Bone and Mineral Research, 2009
- RelA/p65 promotes osteoclast differentiation by blocking a RANKL-induced apoptotic JNK pathway in miceJournal of Clinical Investigation, 2008
- Prevention of free fatty acid–induced hepatic lipotoxicity by 18β-glycyrrhetinic acid through lysosomal and mitochondrial pathwaysHepatology, 2008
- Osteoclast differentiation and activationNature, 2003
- Bone Resorption by OsteoclastsScience, 2000